In conclusion, this analysis revealed that FMO2 was lower expressed in breast cancer compared with normal tissues and contributes to subtype classification and prognosis prediction with co-expressed SFRP1, which could be considered as a predictive biomarker for breast cancer treatment indecently of the Wnt signal pathway by affecting the extracellular matrix. The gene discussed is SFRP1; the disease is breast cancer.